# negative symptoms of schizophrenia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/negative-symptoms-of-schizophrenia

> 2 upcoming FDA catalysts in negative symptoms of schizophrenia: roluperidone (NERV) on December 2027 (primary completion); roluperidone (NERV) on Dec 2027 to Mar 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2024 | [NUPLAZID (pimavanserin) topline data readout](https://sec-api.dev/pdufa/pimavanserin) | ACAD | negative symptoms of schizophrenia | completed, negative | "In March 2024 we reported top-line results from a Phase 3 study of pimavanserin for the treatment of the negative symptoms of schizophrenia." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1070494/000119312526072519/acad-20251231.htm)) |
| December 2027 | [Roluperidone primary completion](https://sec-api.dev/pdufa/roluperidone) | NERV | Negative Symptoms of Schizophrenia | scheduled | "NCT07565428 (Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Minerva Neurosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07565428)) |
| Dec 2027 to Mar 2028 | [Roluperidone topline data readout](https://sec-api.dev/pdufa/roluperidone) | NERV | Negative Symptoms of Schizophrenia | scheduled | "NCT07565428 (Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Minerva Neurosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07565428)) |

## Drugs

- [NUPLAZID (pimavanserin)](https://sec-api.dev/pdufa/pimavanserin) (ACAD)
- [Roluperidone](https://sec-api.dev/pdufa/roluperidone) (NERV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/negative-symptoms-of-schizophrenia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "negative symptoms of schizophrenia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/negative-symptoms-of-schizophrenia

```bibtex
@misc{secapidev_indications_negative_symptoms_of_schizophrenia_20261116,
  title        = {negative symptoms of schizophrenia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/negative-symptoms-of-schizophrenia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_negative_symptoms_of_schizophrenia_20261116","title":"negative symptoms of schizophrenia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/negative-symptoms-of-schizophrenia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
